Patents by Inventor Michael A. Firer

Michael A. Firer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11944091
    Abstract: The present subject matter relates to a stable pesticidal formulation which exhibits improved dispersibility in cold water and full compatibility with fertilizers.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: April 2, 2024
    Assignee: ADAMA MAKHTESHIM LTD.
    Inventors: Shlomo Levy, Michael Berkovitch, Viacheslav Firer
  • Patent number: 10421785
    Abstract: Peptides effective as delta opioid receptor agonists and compositions comprising same are provided. Further provided are methods for targeting medical conditions amenable to treatment with an opioid receptor agonist, including but not limited to, conditions involving pain as well as reducing cocaine craving.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: September 24, 2019
    Assignees: BAR-ILAN UNIVERSITY, ARIEL SCIENTIFIC INNOVATIONS LTD.
    Inventors: Gal Yadid, Michael Firer, Rachela Popovtzer
  • Publication number: 20190117680
    Abstract: A multifunctional molecular platform is provided, for covalent binding of two or more therapeutic or diagnostic agents, and for their sequential release in a biological environment near desired target sites. The platform is used in the preparation of pharmaceutical compositions for treating abnormal cell proliferation, infections, and inflammation.
    Type: Application
    Filed: November 14, 2018
    Publication date: April 25, 2019
    Applicant: Ariel-University Research and Development Company Ltd.
    Inventors: Gary GELLERMAN, Michael A. FIRER
  • Patent number: 10092565
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminescent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: October 9, 2018
    Assignees: Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
    Inventors: Bernard S. Green, Galia Luboshits, Michael A. Firer
  • Publication number: 20170291922
    Abstract: Peptides effective as delta opioid receptor agonists and compositions comprising same are provided. Further provided are methods for targeting medical conditions amenable to treatment with an opioid receptor agonist, including but not limited to, conditions involving pain as well as reducing cocaine craving.
    Type: Application
    Filed: April 10, 2017
    Publication date: October 12, 2017
    Inventors: Gal YADID, Michael FIRER, Rachela POPOVTZER
  • Publication number: 20170080097
    Abstract: A multifunctional molecular platform is provided, for covalent binding of two or more therapeutic or diagnostic agents, and for their sequential release in a biological environment near desired target sites. The platform is used in the preparation of pharmaceutical compositions for treating abnormal cell proliferation, infections, and inflammation.
    Type: Application
    Filed: October 5, 2016
    Publication date: March 23, 2017
    Applicant: Ariel-University Research and Development Company Ltd.
    Inventors: Gary GELLERMAN, Michael A. FIRER
  • Publication number: 20170014410
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminescent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Applicants: Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
    Inventors: Bernard S. GREEN, Galia LUBOSHITS, Michael A. FIRER
  • Patent number: 9464079
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminiscent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: October 11, 2016
    Assignees: Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
    Inventors: Bernard S. Green, Galia Luboshits, Michael A. Firer
  • Publication number: 20140010867
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminiscent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Application
    Filed: March 22, 2012
    Publication date: January 9, 2014
    Applicants: Ariel-University Research and Development Company Ltd., Semorex Technologies Ltd.
    Inventors: Bernard S. Green, Galia Luboshits, Michael A. Firer
  • Publication number: 20100297762
    Abstract: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.
    Type: Application
    Filed: August 5, 2010
    Publication date: November 25, 2010
    Applicant: Ariel-University Research and Developmemt Company Ltd.
    Inventors: Michael A. FIRER, Raisa Laptev
  • Patent number: 7772179
    Abstract: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: August 10, 2010
    Assignee: Ariel-University Research and Development Company Ltd.
    Inventors: Michael A. Firer, Raisa Laptev
  • Publication number: 20100105857
    Abstract: A multifunctional molecular platform is provided, for covalent binding of two or more therapeutic or diagnostic agents, and for their sequential release in a biological environment near desired target sites. The platform is used in the preparation of pharmaceutical compositions for treating abnormal cell proliferation, infections, and inflammation.
    Type: Application
    Filed: October 11, 2007
    Publication date: April 29, 2010
    Inventors: Gary Gellerman, Michael Firer
  • Publication number: 20090054306
    Abstract: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.
    Type: Application
    Filed: April 20, 2006
    Publication date: February 26, 2009
    Applicant: Ariel-University Research and Development Company Ltd.
    Inventors: Michael A Firer, Raisa Laptev